Anagrelide controlled release - Galena Biopharma

Drug Profile

Anagrelide controlled release - Galena Biopharma

Alternative Names: Anagrelide CR - Galena Biopharma; CR anagrelide - Galena Biopharma; GALE-401

Latest Information Update: 19 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BioVascular
  • Developer Galena Biopharma
  • Class 3-ring heterocyclic compounds; Antiplatelets; Imidazoles; Quinazolines; Small molecules
  • Mechanism of Action Type 3 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Essential thrombocythaemia
  • No development reported Chronic myeloid leukaemia; Myelofibrosis; Polycythaemia vera

Most Recent Events

  • 11 Sep 2017 Galena BioPharma and BioVascular amend their license agreement for Anagrelide controlled release
  • 12 Jul 2017 Anagrelide controlled release - Galena Biopharma is available for licensing as of 12 Jul 2017.
  • 11 Mar 2017 Anagrelide controlled release is still at phase II development stage for Essential thrombocythaemia in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top